Evidence map›Paper›PMID 34285940›Full record

ArticleInternational journal of particle therapy2021

Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience.

G Brandon Gunn, Adam S Garden, Rong Ye, Noveen Ausat, Kristina R Dahlstrom, William H Morrison, C David Fuller, Jack Phan, Jay P Reddy, Shalin J Shah and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of particle therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. ACR-ARS Practice Parameter for the Performance of Proton Beam Therapy.International journal of particle therapy · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

G Brandon GunnDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adam S GardenDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rong YeDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Noveen AusatDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kristina R DahlstromDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
William H MorrisonDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C David FullerDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jack PhanDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jay P ReddyDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shalin J ShahDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lauren L MayoDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stephen G ChunDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gregory M ChronowskiDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amy C MorenoDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffery N MyersDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ehab Y HannaDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bita EsmaeliOphthalmic Plastic Surgery, Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maura L GillisonDepartment of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Renata FerrarottoDepartment of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Katherine A HutchesonDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark S ChambersDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lawrence E GinsbergDepartment of Neuroradiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adel K El-NaggarDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David I RosenthalDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiaorong Ronald ZhuDepartment of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steven J FrankDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo characterize our experience and the disease control and toxicity of proton therapy (PT) for patients with head and neck cancer (HNC). PATIENTS AND

methodsClinical outcomes for patients with HNC treated with PT at our institution were prospectively collected in 2 institutional review board-approved prospective studies. Descriptive statistics were used to summarize patient characteristics and outcomes. Overall survival, local-regional control, and disease-free survival were estimated by the Kaplan-Meier method. Treatment-related toxicities were recorded according to the Common Terminology Criteria for Adverse Events (version 4.03) scale.

resultsThe cohort consisted of 573 patients treated from February 2006 to June 2018. Median patient age was 61 years. Oropharynx (33.3%; n = 191), paranasal sinus (11%; n = 63), and periorbital tissues (11%; n = 62) were the most common primary sites. Patients with T3/T4 or recurrent disease comprised 46% (n = 262) of the cohort. The intent of PT was definitive in 53% (n = 303), postoperative in 37% (n = 211), and reirradiation in 10% (n = 59). Median dose was 66 Gy (radiobiological equivalent). Regarding systemic therapy, 43% had received concurrent (n = 244), 3% induction (n = 19), and 15% (n = 86) had both. At a median follow-up of 2.4 years, 88 patients (15%) had died and 127 (22%) developed disease recurrence. The overall survival, local-regional control, and disease-free survival at 2 and 5 years were, respectively, 87% and 75%, 87% and 78%, and 74% and 63%. Maximum toxicity (acute or late) was grade 3 in 293 patients (51%), grade 2 in 234 patients (41%), and grade 1 in 31 patients (5%). There were 381 acute grade 3 and 190 late grade 3 unique toxicities across 212 (37%) and 150 (26%) patients, respectively. There were 3 late-grade 4 events across 2 patients (0.3%), 2 (0.3%) acute-grade 5, and no (0%) late-grade 5 events.

conclusionsThe overall results from this prospective study of our initial decade of experience with PT for HNC show favorable disease control and toxicity outcomes in a multidisease-site cohort and provide a reference benchmark for future comparison and study.

Indexed as

head and neck cancerproton therapysurvivaltoxicity

Identifiers

PMID34285940
PMCPMC8270083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.